Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 15/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 15/20 | 0.39 |
| ▸ | HTR2C | P28335 | 4/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | NNMT | P40261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3213697 | 0.86 | MTNR1A (0.40) | PTGS2MTNR1AMTNR1BHTR2CPOLB | |
| SCHEMBL1711841 | 0.84 | MTNR1A (0.41) | PTGS2MTNR1AMTNR1BHTR2CPOLB | |
| SCHEMBL1711856 | 0.81 | MTNR1A (0.41) | PTGS2MTNR1AMTNR1BHTR2CPOLB | |
| SCHEMBL3400408 | 0.79 | POLB (0.40) | PTGS2MTNR1AMTNR1BHTR2CPOLB | |
| SCHEMBL3229950 | 0.78 | PTGS2 (0.40) | PTGS2MTNR1AMTNR1BHTR2CPOLB | |
| SCHEMBL1712087 | 0.78 | PTGS2 (0.38) | PTGS2MTNR1AMTNR1BHTR2CPOLB | |
| SCHEMBL1711951 | 0.76 | PTGS2 (0.37) | PTGS2MTNR1AMTNR1B | |
| SCHEMBL1723421 | 0.75 | MAPT (0.37) | PTGS2MTNR1AMTNR1BPOLB | |
| SCHEMBL3406716 | 0.74 | PTGS2 (0.37) | PTGS2MTNR1AMTNR1BHTR2CNNMT | |
| SCHEMBL3214175 | 0.74 | PTGS2 (0.35) | PTGS2MTNR1AMTNR1BHTR2CPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9822114-B2 | Tricyclic oxazolidinone antibiotic compounds | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-11-21 | — | — | US | disclosed |
| US-20160237088-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | IDORSIA PHARMACEUTICALS LTD (CH) | 2016-08-18 | — | — | US | disclosed |
| US-9346804-B2 | Tricyclic oxazolidinone antibiotic compounds | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-05-24 | — | — | US | disclosed |
| US-20140142093-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-05-22 | — | — | US | disclosed |
| US-8618092-B2 | Tricyclic oxazolidinone antibiotic compounds | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-12-31 | — | — | US | disclosed |
| US-20110195961-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-08-11 | — | — | US | disclosed |
| EP-2344495-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | Actelion Pharmaceuticals Ltd. (CH) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010041194-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195961-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | HRH3, OXA1L, HRH1 | PTGS2 4023/4885MTNR1A 987/4885MTNR1B 670/4885 |
| US-20160237088-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | H1-3, HRH3, HRH4 | PTGS2 3735/4885MTNR1A 1089/4885MTNR1B 860/4885 |
| US-20140142093-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | OXA1L, H1-3, NGLY1 | PTGS2 4066/4885MTNR1A 1119/4885MTNR1B 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.